PBYI — PUMA BIOTECHNOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401667 ·
Last close
$7.14
Market Cap
$369.13M
52W High
$11.50
52W Low
$4.80
ADV30
441,890
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 56,502,000 | 44,027,000 | 7,585,000 | 8,189,000 | 192,736,000 | 36,537,000 | 54,192,000 |
| Mar 2026 | 44,814,000 | 34,390,000 | -3,828,000 | -3,753,000 | 192,699,000 | 36,193,000 | 64,283,000 |
| Dec 2025 | 75,453,000 | 52,326,000 | 17,106,000 | 13,438,000 | 216,302,000 | 29,635,000 | 85,962,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$46,038,000
Investing CF
$-26,245,000
Financing CF
$-33,861,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.46
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,273,383,000
Inventory
$11,491,000
Receivables
$32,828,000
ST Investments
$67,027,000
EBIT TTM
$30,127,000
Pretax Income TTM
$28,097,000
Interest Exp TTM
$2,030,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$231,824,992
EBITDA
$35,547,000
Free Cash Flow
$37,679,876
Enterprise Value
$297,987,232
Total Cash
$108,575,000
Total Debt
$4,866,000
Shares Out
51,698,356
Trailing EPS
$0.46
Book Value
$2.84
ROE
18.2%
ROA
8.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 228,371,000 | 37,299,000 | 31,111,000 | 216,302,000 | 85,962,000 | 130,340,000 | 41,802,000 |
| Dec 2024 | 230,468,000 | 30,966,000 | 30,278,000 | 213,333,000 | 121,208,000 | 92,125,000 | 38,918,000 |
| Dec 2023 | 235,637,000 | 32,640,000 | 21,591,000 | 230,528,000 | 177,086,000 | 53,442,000 | 27,009,000 |
| Dec 2022 | 228,031,000 | 30,720,000 | 2,000 | 222,059,000 | 200,451,000 | 21,608,000 | -15,827,000 |
TTM Snapshot
Revenues TTM
$231,244,000
NetIncome TTM
$26,718,000
OpCashFlow TTM
—
Assets (Latest)
$192,736,000
Forward EPS
$0.35
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $7.22 · call volume: 23 · put volume: 27
Expected Move to 2026-12-18:
±$1.65
(22.85%) —
implied range
$5.57 –
$8.87
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NIKA | NIKA PHARMACEUTICALS, INC | $369.14M | $0.35 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $366.93M | $3.65 | — |
| CRMD | CorMedix Inc. | $371.44M | $4.67 | — |
| CYDY | CytoDyn Inc. | $366.64M | $0.25 | — |
| PEPG | PepGen Inc. | $365.73M | $3.88 | — |
News headlines (Yahoo Finance, 1h cache)
Puma Biotechnology Inc (PBYI) (Q3 2026) Earnings Call Highlights: Debt-Free and Raising ...
2026-11-06 23:11 · Yahoo
Puma Biotechnology (PBYI) Q3 2026 Earnings Call Transcript
2026-11-06 17:33 · Yahoo
Puma Biotechnology, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Puma Biotech: Q3 Earnings Snapshot
2026-11-05 22:17 · Yahoo
Puma Biotechnology Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
2026-10-22 20:11 · Yahoo
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
2026-10-20 12:40 · Yahoo
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
2026-10-19 12:00 · Yahoo
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-18 14:48 · Yahoo
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
2026-09-17 20:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.